Latest Insider Transactions at Inari Medical, Inc. (NARI)
This section provides a real-time view of insider transactions for Inari Medical, Inc. (NARI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Inari Medical, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Inari Medical, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2023
|
Hill, Mitch C. Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,500
-1.82%
|
$383,500
$59.63 P/Share
|
|
Jun 12
2023
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+3.49%
|
$0
$0.46 P/Share
|
|
May 27
2023
|
Kirk G. Nielsen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,982
+4.63%
|
-
|
|
May 27
2023
|
Jonathan D Root Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,982
+0.55%
|
-
|
|
May 27
2023
|
Donald B Milder Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,982
+1.16%
|
-
|
|
May 18
2023
|
Kirk G. Nielsen Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,412
+3.96%
|
-
|
|
May 18
2023
|
Cynthia L Lucchese Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,412
+6.57%
|
-
|
|
May 18
2023
|
Robert Keith Warner Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,412
+23.11%
|
-
|
|
May 18
2023
|
Catherine M. Szyman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,412
+11.64%
|
-
|
|
May 18
2023
|
Dana G Mead Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,412
+25.57%
|
-
|
|
May 18
2023
|
Jonathan D Root Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,412
+0.45%
|
-
|
|
May 18
2023
|
William Hoffman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,412
+0.21%
|
-
|
|
May 18
2023
|
Rebecca Chambers Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,412
+26.23%
|
-
|
|
May 18
2023
|
Donald B Milder Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,412
+0.95%
|
-
|
|
May 17
2023
|
Thomas Tu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,751
-1.1%
|
$879,819
$69.19 P/Share
|
|
May 17
2023
|
Andrew Hykes President and CEO |
SELL
Open market or private sale
|
Direct |
18,760
-1.18%
|
$1,294,440
$69.19 P/Share
|
|
May 17
2023
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
41,891
-1.21%
|
$2,890,479
$69.19 P/Share
|
|
May 16
2023
|
Thomas Tu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,176
-1.02%
|
$852,320
$70.87 P/Share
|
|
May 16
2023
|
Andrew Hykes President and CEO |
SELL
Open market or private sale
|
Direct |
17,916
-1.09%
|
$1,254,120
$70.87 P/Share
|
|
May 16
2023
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
40,006
-1.11%
|
$2,800,420
$70.87 P/Share
|
|
May 15
2023
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
25,000
-0.34%
|
$1,750,000
$70.52 P/Share
|
|
May 12
2023
|
Hill, Mitch C. Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,750
-1.76%
|
$892,500
$70.3 P/Share
|
|
May 12
2023
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+3.38%
|
$0
$0.46 P/Share
|
|
Apr 17
2023
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
25,000
-0.5%
|
$1,600,000
$64.72 P/Share
|
|
Apr 12
2023
|
Hill, Mitch C. Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,750
-0.85%
|
$816,000
$64.76 P/Share
|
|
Apr 12
2023
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+3.27%
|
$0
$0.46 P/Share
|
|
Apr 01
2023
|
William Hoffman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,018
-0.08%
|
$123,098
$61.74 P/Share
|
|
Apr 01
2023
|
Hill, Mitch C. Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,572
-0.28%
|
$95,892
$61.74 P/Share
|
|
Apr 01
2023
|
Andrew Hykes President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,999
-0.12%
|
$121,939
$61.74 P/Share
|
|
Apr 01
2023
|
Thomas Tu Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,125
-0.09%
|
$68,625
$61.74 P/Share
|
|
Mar 20
2023
|
Andrew Hykes President and CEO |
SELL
Open market or private sale
|
Direct |
9,000
-0.8%
|
$576,000
$64.46 P/Share
|
|
Mar 15
2023
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
25,000
-0.33%
|
$1,575,000
$63.28 P/Share
|
|
Mar 15
2023
|
William Hoffman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+1.92%
|
$0
$0.43 P/Share
|
|
Mar 14
2023
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
5,000
-0.4%
|
$300,000
$60.1 P/Share
|
|
Mar 13
2023
|
Hill, Mitch C. Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,750
-1.09%
|
$739,500
$58.03 P/Share
|
|
Mar 13
2023
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+3.15%
|
$0
$0.46 P/Share
|
|
Mar 12
2023
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
125,393
+39.35%
|
-
|
|
Mar 12
2023
|
Andrew Hykes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
430,517
+43.42%
|
-
|
|
Mar 12
2023
|
William Hoffman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
961,350
+43.33%
|
-
|
|
Mar 12
2023
|
Thomas Tu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
292,584
+42.26%
|
-
|
|
Feb 27
2023
|
Thomas Tu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.36%
|
$560,000
$56.8 P/Share
|
|
Feb 27
2023
|
Thomas Tu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.87%
|
$0
$0.46 P/Share
|
|
Feb 21
2023
|
Andrew Hykes President and CEO |
SELL
Open market or private sale
|
Direct |
9,000
-6.45%
|
$495,000
$55.19 P/Share
|
|
Feb 18
2023
|
Hill, Mitch C. Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,412
+23.98%
|
-
|
|
Feb 18
2023
|
Andrew Hykes President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
46,549
+25.01%
|
-
|
|
Feb 18
2023
|
Thomas Tu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,412
+16.66%
|
-
|
|
Feb 15
2023
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
50,000
-1.7%
|
$2,900,000
$58.24 P/Share
|
|
Feb 13
2023
|
Hill, Mitch C. Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,750
-5.78%
|
$675,750
$53.95 P/Share
|
|
Feb 13
2023
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+9.89%
|
$0
$0.46 P/Share
|
|
Jan 27
2023
|
Thomas Tu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-1.82%
|
$610,000
$61.38 P/Share
|